Liposomal delivery is a well-established approach to increase the therapeutic index of drugs, mainly in the field of cancer chemotherapy. Here, we report the preparation and characterization of a new liposomal formulation of a derivative of lomeguatrib, a potent O6-methylguanine-DNA methyltransferase (MGMT) inactivator. The drug had been tested in clinical trials to revert chemoresistance, but was associated with a low therapeutic index. A series of lomeguatrib conjugates with distinct alkyl chain lengths -i.e. C12, C14, C16, and C18 -was synthesized, and the MGMT depleting activity as well as cytotoxicity were determined on relevant mouse and human glioma cell lines. Drug-containing liposomes were prepared and characterized in terms of loading and in vitro release kinetics. The lipophilic lomeguatrib conjugates did not exert cytotoxic effects at 5 M in the mouse glioma cell line and exhibited a similar MGMT depleting activity pattern as lomeguatrib. Overall, drug loading could be improved by up to 50-fold with the lipophilic conjugates, and the slowest leakage was achieved with the C18 derivative. The present data show the applicability of lipophilic lomeguatrib derivatization for incorporation into liposomes, and identify the C18 derivative as the lead compound for in vivo studies.
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Introduction
Liposomes have successfully been used as carriers to ameliorate the therapeutic index of chemotherapeutic drugs such as doxorubicin, daunorubicin and more recently vincristine and irinotecan (Gill et al., 1996; Ko et al., 2011; O'Brien et al., 2010; O'Brien et al., 2004) .
Passive as well as active loading methods allow the encapsulation of a broad range of drugs, from hydrophilic to amphiphilic and lipophilic molecules, in either the hydrophilic aqueous core or the surrounding phospholipid lipid bilayer. While the entrapment of polar drugs is often associated with low efficiency, it can be improved substantially by remote loading procedures as long as the compounds are ionizable and sufficiently membrane-permeable, which is the case with several notable examples on the market such as doxorubicin and vincristine sulfate liposomes (Doxil ® or Marqibo ® , respectively) (Boman et al., 1993; Haran et al., 1993; Mayer et al., 1990) . Some classes of molecules, however, remain difficult to load into liposomes. For example, non-glycosylated purine analogues are mostly insoluble in water and show only marginal solubility in organic solvents. Gulati et al. termed this class of amphiphobic compounds as "biphasic insoluble drugs" (Gulati et al., 1998) . Indeed, the biphasic insoluble nature of drugs like allopurinol, 8-azaguanine, and 6-mercaptopurine makes them challenging candidates for liposomal formulations, as neither interactions with the lipid bilayer nor stable retention in the inner core can be achieved (Fendler and Romero, 1976; Liautard et al., 1991; Taneja et al., 2000) .
Lipophilic derivatization is an effective strategy for the improvement of drug loading in liposomes (Gabizon et al., 2006) that has enabled formulations with increased drug entrapment by several thousand-fold (Sasaki et al., 1987; Tokunaga et al., 1988) . In this process, a lipophilic anchor is covalently conjugated to the drug of interest, often via biodegradable linkers (e.g. ester, disulfide), which dock the pharmaceutical active component at the liposomal bilayer.
Lomeguatrib (or O 6 BTG, short for O 6 -(4-bromothenyl)guanine) is a purine analogue with biphasic insoluble properties, and a potent inactivator and pseudo-substrate of the O 6methylguanine-DNA methyltransferase (MGMT). Firstly synthesized in the early 90's, O 6 BTG showed greater in vitro potency compared to O 6 -benzylguanine (O 6 BG), the very first MGMT inactivator tested in humans. Clinically, O 6 BTG has been evaluated for its ability to counteract MGMT-induced resistance against triazene-based chemotherapeutics such as temozolomide (Ranson et al., 2006) and dacarbazine (Tawbi et al., 2011) . Unfortunately, O 6 BTG potentiated the hematological toxicity of alkylating antineoplastic agents at effective dosage, a downside shared with several other MGMT inactivators, which precluded any advantage over the treatment with antineoplastic agent alone (Kefford et al., 2009; Khan et al., 2008; Ranson et al., 2006; Sabharwal et al., 2010) . In the early 2000s, the group of Wiessler addressed the drug's tumor-specificity and aqueous solubility by linking glucose to O 6 BTG (Reinhard et al., 2001a; Reinhard et al., 2001b) . The authors examined the ability of a series of conjugates to inactivate MGMT as a function of spacer length, revealing that a minimum of 8 carbon atoms (C8) in the spacer arm were required for adequate depletion activity. Nonetheless, their lead compound, 8-[O 6 -(4-bromothenyl)-guan-9-yl]-octyl-β-Dglucoside (O 6 BTG-C8-Glu), induced higher cytotoxicity than O 6 BTG. While information regarding the water-solubility of O 6 BTG-C8-Glu was not provided in the study, the strong hydrophobic character of the linker would suggest that only a small solubility improvement was achieved. Given the hematological toxicity of O 6 BTG in humans when combined with alkylating agents, we hypothesized that the incorporation of O 6 BTG into liposomes could improve the drug's therapeutic index by altering its biodistribution profile. Capitalizing on the benefits of long-circulating poly(ethylene glycol)-modified liposomes, the proposed approach could enhance drug deposition in tumors exhibiting an innate enhanced permeability and retention (EPR) effect. Moreover,O 6 BTG-loaded liposomes could also constitute a valid therapeutic strategy for challenging neoplasms largely lacking an EPR effect (Gao et al., 2013) , e.g. glioblastoma multiforme, provided strategies to locally permeabilize the BBB are put in place, such as microbubble-enhanced focused ultrasound (FUS) (Treat et al., 2007; Treat et al., 2012) .
In this work, the development of a liposomal formulation of O 6 BTG suitable for parenteral administration is described. A series of alkylated O 6 BTG derivatives (O 6 BTG-Cn) was synthesized with chain lengths ranging from C12 to C18 with the aim of increasing O 6 BTG loading in liposomes. The impact of the lipophilic anchor conjugation on the derivatives' MGMT depleting activity and cytotoxic properties were assessed in temozolomide-resistant glioma cells. Furthermore, liposomes loaded with the O 6 BTG derivatives were prepared and characterized. Based on the obtained experimental results, a promising lead formulation with highly favorable in vitro performance was identified for in vivo studies.
Materials and Methods

Materials
Chloroform, cholesterol (CHOL), dimethyl sulfoxide ( 
Synthesis of O 6 BTG derivatives
The synthesis of lipophilic O 6 BTG derivatives (O 6 BTG-Cn) was adapted after Kjellberg et al.
and Reinhard et al. (Fig. 1) (Kjellberg et al., 1986; Reinhard et al., 2001b) . Briefly, LiH (9.7 mg, 1.23 mmol) was suspended in 6. 
Cell culture
SMA-497 mouse glioma cells and LN-18 human glioma cells were grown in complete medium (DMEM supplemented with 10% FBS and 2 mM L-glutamine) in a humidified atmosphere of 5% CO2 at 37 °C and routinely passaged 2-3 times per week. For cytotoxicity and MGMT depleting experiments, cells were grown to about 80% confluence before use.
Both cell lines were regularly tested for the absence of mycoplasma. More specific culture conditions are given in the respective sections.
MGMT depleting activity of O 6 BTG-Cn
The MGMT depleting activity of the O 6 BTG-Cn derivatives was assessed by Western blot adapting a protocol from Towbin et al. (Towbin et al., 1979) . Cells (2 x 10 5 per well) were seeded in 6-well plates, grown for 24 h and exposed to increasing concentrations of O 6 BTG-Cn (N9) for another 24 h. The medium was then replaced and after 72 h the cells were lysed with lysis buffer (25 mM Tris-HCl, 120 mM sodium chloride, 5 mM EDTA, 0.5% NP40 cell lysis buffer) (Seystahl et al., 2015) . Total protein (30 μg/lane) was separated on a 12% acrylamide gel. After transfer to nitrocellulose membranes, the blots were blocked for 1 h in 5% milk-Tris-buffered saline with polysorbate 20, and incubated overnight at 4 °C with the respective primary antibodies (anti-human MGMT, anti-murine MGMT or anti-β-actin). The membranes were then washed and incubated with secondary antibodies conjugated to HRP (sheep anti-mouse IgG-HRP, goat anti-rat IgG-HRP, and donkey anti-goat IgG-HRP) at room temperature for 1 h. Protein bands were detected using enhanced chemiluminescence by a Curix 60 table-top processor (Agfa, Mortsel, Belgium).
Cytotoxicity experiments
The cytotoxic potential of O 6 BTG-Cns was determined in vitro using a MTS assay Reagent. The cells were incubated for 2 h to reduce the MTS tetrazolium compound into a reddish formazan product, which was subsequently quantified by spectrophotometry at 490 nm with an Infinite M200Pro plate reader (Tecan, Maennedorf, Switzerland).
Preparation of drug-loaded liposomes
Small unilamellar liposomes were prepared by the lipid film hydration/extrusion method (Hope et al., 1985) . 
Cryo-transmission electron microscopy (cryo-TEM)
Five µL of each sample was applied to a copper grid covered by holey carbon film (Quantifoil Multi A Micro Tools GmbH, Jena, Germany) and excess of liquid was blotted automatically between two strips of filter paper. Subsequently, the samples were rapidly plunged into liquid ethane (cooled to ~ 180 °C) in a cryobox (Carl Zeiss NTS GmbH, Oberkochen, Germany).
Excess ethane was removed with a piece of filter paper. The samples were transferred immediately with a Gatan 626 cryo-transfer holder (Gatan, Pleasanton, CA) into the precooled cryo-electron microscope (Philips CM 120, Eindhoven, Netherlands) operated at 120 kV and viewed under low dose conditions. The images were recorded with a 2k CMOS Camera (F216, TVIPS, Gauting, Germany). In order to minimize the noise, four images were recorded and averaged to one image. (Morrison, 1964) .
Determination of drug loading
In vitro release kinetics
Drug release from liposomes was determined in vitro following a protocol developed by Shabbits et al. (2002) . This assay is based on the transfer of lipophilic drugs from donor drugcontaining liposomes to acceptor multilamellar vesicles (MLVs) mimicking the in vivo drug transfer rate to hydrophobic pools. Briefly, donor O 6 BTG-Cn-loaded liposomes were incubated with acceptor MLVs at a 1:100 mol ratio in 4-(2-hydroxyethyl)piperazine-1ethanesulfonic acid (HEPES)-buffered saline for 24 h at 37 °C under constant stirring.
Samples were withdrawn at various times (0, 0.5, 1, 2, 4, 8, and 24 h) and centrifuged at 1600 x g for 10 min to separate acceptor MLVs from donor liposomes, which remained in the supernatant. The drug amount in the supernatant was assessed by high-performance liquid chromatography (HPLC). Details on MLV preparation and drug quantification by HPLC are available as Supplementary Information (S.2).
Statistical analysis
Statistics were performed with SigmaPlot 13.0 software (Systat Software Inc., San Jose, CA).
All data presented are means ± SD of at least three independent samples. One-way ANOVA combined with a Tukey test for pairwise comparison was performed to distinguish differences between test groups defining a p value of ≤ 0.05 as statistically significant.
Results and discussion
Synthesis of O 6 BTG derivatives
The alkylation of O 6 BTG (Fig. 1) was a one-step synthesis with a yield of ca. 80% for the isomeric mixture (Table 1) . O 6 BTG-Cn were prepared from the respective Br-Cn and O 6 BTG via nucleophilic substitution, yielding two different isomers at the respective N7 or N9 position of the guanine moiety. The structures of all O 6 BTG-Cn (N7 and N9) were determined by 1 H-NMR and 13 C-NMR spectroscopies ( Supplementary Information: S.3) . Melting points obtained by DSC were in the range of 112 to 122 °C for the N7 derivatives, and in the range of 99 to 105 °C for the N9 derivatives ( Table 1 ). An increase in chain length led to a decrease in melting points in the N7 isomers, whereas the opposite trend was recorded for the N9 isomers. Both the melting entropy and enthalpy generally increased with increasing chain lengths. For the alkyl chains of the N9 isomer it might, however, be easier to establish van der Waals interactions due to a larger distance to the bromothenyl-residue compared to the N7 isomer. Ordered domains may attenuate the increase in melting entropy as a function of chain length, making the increase in melting enthalpy the dominating factor for the N9 and leading to a rise in melting points Zhang and Maginn, 2014) . With regard to the N7, the enthalpy increase compared to the one of the N9 might be reduced, resulting in a melting point decrease. As previously observed by Kjellberg et al., the chosen synthetic strategy favored the N9 isomer (Kjellberg et al., 1986) . 
MGMT depleting activity of O 6 BTG-Cn
Several former studies evaluating alternative O 6 BTG derivatives have reported that N7substitution of MGMT inactivators consistently resulted in complete loss of MGMT depleting activity (Chae et al., 1994; Moschel et al., 1992) . Based on these findings, we investigated the depleting activity of one N7 isomer, O 6 BTG-C12 (N7), and compared it to its N9 counterpart.
A direct comparison of the two isomers in SMA-497 glioma cells (Fig. 2) revealed that the N9 was more active than the N7. Indeed, the N7 isomer did not show any significant depletion on SMA-497 cells in the tested concentration range. These results confirmed previous work (Chae et al., 1994; Moschel et al., 1992) , and might be explained by the structural similarity between the N9 isomer and the natural target of MGMT, the DNA, in which the nitrogen atom at position 9 of the guanine base is linked to the 1' carbon atom of the deoxyribose. To understand the isomer-dependent depleting activity, we investigated the isomers' binding mechanisms to MGMT using molecular dynamics (MD) simulations. Chemical reactions between the protein and the ligand were not investigated, since this requires a more complex simulation protocol which would go beyond the purpose of this work. The binding site of human MGMT with O 6 BG was used for binding studies with O 6 BTG and O 6 BTG-C12 (N7 and N9) (Wibley et al., 1995; Wibley et al., 2000) . Indeed, the binding mechanism of the active part of the N9 isomer was analogous to the one of O 6 BTG (Figs. 3A, B) ; in addition, the arrangement of the alkyl chain was consistent with the findings reported for O 6 BTG-C8-Glu (N9) by Reinhard et al. (Reinhard et al., 2001c) . Interestingly, the N7 isomer also exhibited a similar pose within the binding pocket ( Fig. 3C) , but the binding stability was dependent on the orientation of the aliphatic chain. Unbinding events that destabilized the protein-ligand interaction were found when the alkyl chain was oriented similarly to the one of the N9 isomer as illustrated in Fig. 3D . However, stable binding is most likely a prerequisite for the covalent reaction between protein and MGMT inhibitors, explaining the poor MGMT depleting activity of the N7 isomer. An additional set of simulations was performed for O 6 BTG-C18 (N7 and N9); molecular trajectories showed a behavior analogous to O 6 BTG-C12 isomers. A detailed discussion of the performed MD simulations is provided in the Supporting Information (S.4). Given the confirmed superior MGMT depleting effect, the N9 derivatives were selected for all further experiments.
The impact of the alkyl chain length on the drug activity of the N9 isomers was then evaluated by monitoring the levels of intracellular MGMT protein levels on SMA-497 and LN-18 cells at increasing O 6 BTG-Cn concentrations. As illustrated in Fig. 4, all (Crone et al., 1994) . 
In vitro cytotoxicity of O 6 BTG-Cn (N9)
The cytotoxicity of the O 6 BTG-Cn (N9) derivatives was assessed in murine SMA-497 and human LN-18 cells, and compared to those of the parent drug and two established MGMT inactivators, namely O 6 BG and O 6 BTG-C8-Glu. Similar to the parent drug, a concentrationdependent decrease of cell viability was found for all derivatives in both cell lines, with a more prominent effect in LN-18 cells ( Figs. 5 A-D) . Although MGMT inactivators are not expected to be highly cytotoxic given that their target protein does not hold  to current knowledge  housekeeping tasks in the cell (Margison et al., 2003; Tsuzuki et al., 1996) Fig. 5   D) . O 6 BTG-C18, the derivative with the longest alkyl chain, did not show prominent toxicity in the tested concentration range, and was in fact significantly less toxic than O 6 BTG at 10-40 μM in SMA-497 cells and 5-20 μM in LN-18 cells (Figs. 5 B, D) . It is noteworthy that toxic effects appeared to be inversely related to the alkyl chain length in both cell lines. Given their strong lipophilic nature, the O 6 BTG-Cn derivatives might bear a greater potential to permeate biological membranes than the parent drug O 6 BTG, making them more likely to reach the intracellular space. With regard to the alkyl chain length, derivatives with longer chains might associate with plasma membranes more strongly, minimizing further transfer to subcellular compartments and, in turn decreasing cytotoxic effects as demonstrated for O 6 BTG-C18 (Locatelli et al., 2008) . 
Characterization and drug loading of liposomal O 6 BTG-Cn formulations
The different O 6 BTG-Cn were passively loaded into DOPC-based liposomes using the lipid film hydration method followed by extrusion. Empty and drug-loaded liposomes had a mean hydrodynamic diameter of ca. 75 nm with a PDI below 0.2 ( Supplementary Information: S.5) .
Considering that tumoral deposition depends on nanoparticle size, the obtained hydrodynamic diameter might be suitable for passive delivery via the EPR effect alone or preferably in combination with localized BBB permeabilization, for instance with microbubble-enhanced FUS (Sunoqrot et al., 2014; Treat et al., 2007) . Cryo-TEM-based images of empty and O 6 BTG-C18-loaded liposomes (4 mol%) showed mainly spherical unilamellar particles with very few bi-lamellar and invaginated liposomes (Fig. 6) . No drug precipitates were apparent in the recorded images. Drug loadings of O 6 BG, O 6 BTG, O 6 BTG-C8-Glu, and O 6 BTG-Cn were measured and compared at an initially added drug concentration of 4 mol% (Fig. 7) . O 6 BG and O 6 BTG revealed loadings of <0.02 mol% and 0.08 ± 0.03 mol%, respectively, with entrapment efficiencies below or equal to 2%. The use of O 6 BTG conjugated to an octyl-glucose linker led to a 10-fold increase in drug loading (0.87 ± 0.13 mol%), likely a result of a stronger hydrophobic interaction of the C8-moiety with the liposomal bilayer. O 6 BTG conjugations with simple alkyl chains gave rise to significantly increased loadings, reaching entrapment efficiencies of more than 85%. 
Liposomal drug retention in vitro
The release kinetics of the liposomal formulation was monitored in vitro over 24 h at 37 °C with an assay using MLVs as acceptor compartment (Shabbits et al., 2002) . The release rates correlated with the alkyl chain length (Fig. 9) . The O 6 BTG-C12 and O 6 BTG-C14 derivatives were transferred very quickly to the surrounding MLVs and already after 1 h, more than 60% of the loaded drug had distributed to the MLV population. O 6 BTG-C16 was transferred to an extent lower than 30% within the same time frame, while with O 6 BTG-C18 the drug retention was much higher and less than 40 and 60% of the C18 derivative was released after 8 h and 24 h, respectively. The improved liposomal retention observed for O 6 BTG-Cn with longer alkyl chains can be attributed to an increase of hydrophobic interactions with the lipid bilayer, which would stabilize the drugs' anchoring (Shabbits et al., 2002) . It is important to mention that the alkyl chain length of O 6 BTG-C18 is identical to the main lipid of our liposomal formulation, DOPC, which might minimize membrane perturbation while enhancing membrane embedding for this derivative.
With regard to a future in vivo application, the incorporation of O 6 BTG-C18 into longcirculating PEGylated liposomes may be suitable for the enhancement of the drug's biological half-life, a prerequisite for improved tumor deposition, while ensuring sustained release at the tumoral site.
Conclusion
This study presents several novel long-circulating liposomal formulations of MGMT inactivator derivatives that may increase the tumor deposition via the EPR-effect and/or after localized BBB permeabilization. Given the marginal liposomal loading of highly potent but low tumor-specific MGMT inactivators such as O 6 BG and O 6 BTG, lipophilic drug derivatization was utilized to increase liposomal incorporation. The MGMT depleting activity of O 6 BTG was preserved in the lipophilic conjugates, and especially in the derivative with the longest alkyl chain length (C18), which did not exhibit conspicuous cytotoxicity, and was in fact less toxic than O 6 BTG. The sustained drug retention of O 6 BTG-C18 in PEGylated liposomes in combination with the long-circulating behavior of the carrier can alter the drug's biodistribution and improve its in vivo performance, making this liposomal formulation an eligible candidate for future MGMT-induced chemoresistant tumor therapies. The strategy described could potentially be used for other guanine-based MGMT inactivators in the future.
Studies evaluating the in vivo efficacy of O 6 BTG-C18-based liposomes in a glioma-bearing rodent animal model together with temozolomide are currently ongoing.
